Evidence map›Paper›PMID 37012631›Full record

Trial reportAlcohol and alcoholism (Oxford, Oxfordshire)2023

Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial.

Guillaume Airagnes, Rémi Valter, Géraldine Ducoutumany, Clément Vansteene, Jean-Baptiste Trabut, Philip Gorwood, Caroline Dubertret, Joane Matta, Anais Charles-Nelson, Frédéric Limosin

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Alcohol and alcoholism (Oxford, Oxfordshire), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Guillaume AiragnesDepartment of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France.
Rémi ValterDepartment of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France.
Géraldine DucoutumanyDepartment of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France.
Clément VansteeneGHU Paris Psychiatrie et Neurosciences, CMME, Hôpital Sainte-Anne, 1 rue Cabanis, 75014 Paris, France.
Jean-Baptiste TrabutAP-HP, Hôpitaux Universitaires Henri-Mondor, Hôpital Emile ROUX, Department of Addictology, 1 Avenue de Verdun, 94450 Limeil-Brévannes, France.
Philip GorwoodFaculté de Santé, UFR de Médecine, Université Paris Cité, 15 Rue de l'École de Médecine, 75006 Paris, France.
Caroline DubertretFaculté de Santé, UFR de Médecine, Université Paris Cité, 15 Rue de l'École de Médecine, 75006 Paris, France.
Joane MattaINSERM UMS011, Population-based Epidemiological Cohorts, Hôpital Paul Brousse Bât. 15/16, 16 avenue Paul Vaillant-Couturier, 94807 Villejuif Cedex, France.
Anais Charles-NelsonINSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, AP-HP, Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, 20 rue Leblanc, 75015 Paris, France.
Frédéric LimosinDepartment of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France.
Assistance Publique – Hôpitaux de Paris · FRHôpital Paul-Brousse · FRInstitut de Psychiatrie et Neurosciences de Paris · FRCentre Hospitalier Sainte-Anne · FRHôpital Européen · FRUniversité Paris Cité · FR

Funding

French national PHRC
6 · The paper itself

Abstract

objectiveAlcohol withdrawal syndrome (AWS) is a frequent and potentially life-threatening condition experienced in alcohol use disorder. Since hypomagnesemia is involved in AWS's severity, we conducted a multicenter double-blind randomized placebo-controlled trial to examine the efficacy of oral magnesium supplementation as an adjuvant therapy of AWS. MATERIAL AND

methodsInpatients were recruited in six different centers if they had a baseline score higher than eight on the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar). The experimental treatment was magnesium lactate dehydrate, administrated three times per day providing a total of 426.6 mg per day and up to 15 days. The primary endpoint was the significant between-group difference of the CIWA-Ar total score change from baseline to 3 days later. The treatment group and baseline score were introduced as covariables in an analysis of covariance.

resultsA total of 98 inpatients were included {71.4% of men; mean age of 49.1 years [standard deviation (SD): 10.3]}. In the intention-to-treat population, the mean reduction of the CIWA-Ar score in the experimental group between baseline and 3 days later was 10.1 (SD: 5.2), whereas it was 9.2 (SD: 3.9) in the control group. The absolute difference of the adjusted mean in the experimental group compared with the control group was -0.69 (SD: 0.72), which did not correspond to a significant between-group difference (P = 0.34). Per-protocol analysis and sensitivity analyses also supported this result. Supplementary analyses found no significant difference regarding benzodiazepine consumption, magnesium blood concentration, and satisfaction to care.

conclusionsThe present study does not support the rationale of systematic oral magnesium supplementation in patients with AWS.

Indexed as

AlcoholismMagnesiumSubstance Withdrawal SyndromeAdministration, OralBenzodiazepinesDiarrheaDouble-Blind MethodFemaleHumansMaleMiddle AgedBenzodiazepinesMagnesiumalcohol use disorderalcohol withdrawal syndromebenzodiazepinemagnesiumrandomized controlled trial

Identifiers

PMID37012631
OpenAlexW4362522173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.